medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Title: Sustained SARS-CoV-2 seroprevalence and related hematological features in asymptomatic blood donors

Running Title: COVID-19 seroprevalence and hematimetry

Author names and affiliations:

M Carmen Martín [a]

M Isabel González [a]

Nuria Holgado [a]

Ana I Jimenez [a]

Nuria Ortega [a]

Isabel Page [a]

Alba Parrado [a]

María Pérez [a]

Lydia Blanco-Peris [a]

[a] Centro de Hemoterapia y Hemodonación de Castilla y León, Paseo de Filipinos s/n, 47007 Valladolid, Spain

Corresponding author: M Carmen Martín; cmartinalo@saludcastillayleon.es; Centro de Hemoterapia y Hemodonación de Castilla y León, Paseo de Filipinos s/n, 47007 Valladolid, Spain

Sources of research support

This work has been supported by Roche Diagnostics International Ltd., who provided free equipment and test reagents. Roche Diagnostics International Ltd. was not involved, either in study design, collection, analysis and interpretation of data, the writing of the report or in the decision to submit the article for publication.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Acknowledgements

LB and MCM conceived and designed the study, NH, NO; MP and AP acquired data, IP, AJ and MIGF performed analysis and interpretation of laboratory data, MCM and LB drafted the article and revised it critically for important intellectual content, all authors provided final approval of the version to be submitted.

The authors thank to all blood donors making this work possible by allowing research use of their samples by the Biobanco del Centro de Hemoterapia y Hemodonación de Castilla y León. They also thank the staff in charge of blood donation, and lab technicians for their efforts and Roche for its support.

Ethical considerations

This study was conducted according with national regulations, institutional policies and in the tenets of the Helsinki Declaration. This study was approved by the Valladolid Health Area Drug Research Ethics Committee, in a meeting held on June 11, 2020 with the reference number “BIO-2020-93”. Included donors consented to participate in Biobank research activities. The privacy rights of human subjects were always observed.

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Sustained SARS-CoV-2 seroprevalence and related hematological features in asymptomatic blood donors

Abstract

Background and objectives: COVID-19 can either cause death or go unnoticed but antibodies will remain protecting us of SARS-CoV-2 reinfection for an uncertain time and to a uncertain extent. Knowledge of COVID-19 epidemiological and hematological features should help make a good forecast of resources for possible future outbreaks or vaccination strategies, and would facilitate decisions in the social sphere by a more reliable estimate of the percentage of immunized individuals. Our aim was to describe seroprevalence evolution from summer 2019 to autumn 2020 in Spain and to determine its relationship with age, blood group or haematological parameters.

Materials and methods: Sera and plasma from historical donation archives were randomized and a total of 12,718 samples tested by a Chemiluminiscent analysis for anti SARS-CoV-2 N protein total immunoglobulins. Blood donors were 60.9% males, average age 46+/-13. Sex, age, blood group, blood cell counts and percentages and immunoglobulin concentrations were extracted from electronic recordings.

Results: 6.7% donors were positive by the end of 1st wave. No differences by sex, age or blood group were found regarding antibodies. Leukocyte and neutrophil counts were lower ($p<0.001$) and haemoglobin was lower ($p<0.001$) in positive donations than in negative ones. Sex differences were found in neutrophils, leukocytes, haemoglobin and haematocrit as related to SARS-CoV-2 antibodies.

Conclusions: Seroprevalence due to asymptomatic cases would be slightly lower than the overall one due to age restrictions for blood donors. Sex and age

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

would not affect COVID-19 susceptibility but its severity. Gender differences would be present in asymptomatic individuals. Further studies are needed to confirm these gender differences as they can help better understand the immune response to COVID-19, its pathogenesis and prognosis.

Keywords: COVID-19, antibodies, immunity, seroprevalence, SARS-CoV-2

Abbreviations

Immunoglobulin G (IgG); immunoglobulin A (IgA); immunoglobulin M (IgM); polymerase chain reaction (PCR); standard deviation (SD); interquartile range (IQR); White blood cells (WBC), haemoglobin (Hb), haematocrit (HCT), mean corpuscular volume (MCV).

Introduction

Most SARS-CoV-2 infection cases develop an effective immune response during infection. Even these who curse asymptomatic or with just mild symptoms mount humoral or cell responses. This makes it hard to calculate accurate infection or fatality rates and prevalence [1]. Immunization either due to infection or to vaccination leads to viral eradication and to specific T cell responses and antibodies against SARS-CoV-2, that usually peak 8–15 days after infection [2]. Antibodies that neutralize the virus are the primary protection against COVID-19, and lymphocyte responses augment protection.

Antibody assays are quite different: they either detect antibodies against different viral proteins (S1, S1/S2, RBD or NC) or different immunoglobulin classes: IgG, IgM, IgA or their combinations. It should be noticed that every approved vaccine in Europe to date (May 2020) enhances anti-S responses, whereas an infection leads to a multi specific response to SARS-CoV2 antigens. To make it even

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

messier, many factors can influence test performance, including cross-reactivity with other coronaviruses or platform (laboratory-based vs point-of-care, lateral flow). Chemiluminiscence assays have suitable performances regarding both sensibility and sensitivity while correlation to neutralizing antibodies would be around 0.7 [3].

Our region, Castilla y Leon, with a population of 2.299.598 inhabitants, has accumulated nearly 225.000 COVID-19 confirmed cases (https://analisis.datosabiertos.jcyl.es/), with an overall case-fatality rate of 3.01 to date. Our institution, Centro de Hemoterapia de Castilla y León keeps within its Biobank plasma samples from every single donation along the last ten years, that makes up around one million samples. Any demographic data such as sex or age and laboratory parameters (blood counts, blood group, haemoglobin, etc.…) is as well kept in a database (Hemasoft, eDelphyn).

Blood donor-based serosurveillance is a powerful and cost-effective strategy to monitor infectious diseases. There are quite a lot of infections for which routine donor screening is well known to be useful, including human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), human T-lymphotrophic virus (HTLV), and West Nile virus (WNV) [1], babesiosis or Crimea-Congo fever. The use of blood donor samples means we're sampling mainly asymptomatic and recovered cases of COVID-19 (normal blood donation is allowed after 28 days following COVID-19 symptoms' resolution).

Seroprevalence surveys are then needed to monitor coronavirus pandemic, both before and after vaccination strategies [4]. Reported COVID-19 cases do not represent the full SARS-CoV-2 disease burden due to low detection rates, especially at the beginning of pandemics. Case reports are dependent on patients' seeking health care, massive local screenings or regional tracking activities. Analysis of data from seroprevalence and serosurveillance is a

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

common strategy for estimating underreporting and real disease burden. There are several features that should be taken into account, including time between infection and antibody development or antibody waning, which must be considered to understand seroprevalence surveys avoiding biases. Any seroprevalence survey should be evaluated for selection bias. Serological surveys with a random sampling design of the general population are difficult to perform in a pandemic, but a random sampling design of the general population yields a seroprevalence estimate least likely to be affected by selection bias. Blood donors are a quite representative subset of general population aged 18-65 and our historical plasma collection was big enough to perform a time-layered randomization.

Heterogeneity of susceptibility and transmission is hard to evaluate but does exist [5]. A portion of the population is not susceptible to infection from the first pathogen contact. Some of them may have pre-existing immunity via cross-reactivity or particular host factors such as mucosal immunity or trained innate immunity protection (as it has been reported to be conferred by DTP or BCG vaccination)[6]. There is as well a proportion of seronegative individuals that will develop immunity by T cell mediated responses but without exhibiting an antibody response [7].

The starting hypothesis is the existence of a certain number of asymptomatic carriers of the SARS-CoV-2 virus that would develop antibodies against it [7] (and subsequently contribute to herd immunity). Those asymptomatic cases were unnoticeable before testing began and might had been circulating from an unknown moment. Early cases have been described in France [8], arising the question of whether the pathogen could have been circulating even before the official recording of the first cases. The main aim of this study was to determine what percentage of the population has had contact with SARS-CoV-2 at different

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

times and has therefore developed antibodies against it. A secondary goal was to describe haematological features of seropositive donors and establish whether sex, age, blood group or haematological abnormalities were related COVID-19 exposure.

Knowledge of COVID-19 epidemiological and hematological features should help make a good forecast of resources for possible future outbreaks or vaccination strategies, and would facilitate decisions in the social sphere by a more reliable estimate of the percentage of immunized individuals.

MATERIAL and METHODS

Aim, design and setting of the study

The aim of this study was to analytically obtain, a reliable knowledge of asymptomatic COVID-19 cases and their immunological and haematological characteristics, seroprevalence, rate of positive donations and its temporal evolution along the first wave in Spain. So, a retrospective observational analysis was performed.

Participants

The Biobank is included in the National Registry of Biobanks (RD17 / 16/2011) with the number B.0000264. The institution holds an ISO 9001: 2015 certification endorsing our granting of safety and traceability of any human biological sample we distribute, always behaving Spanish and European rules on human samples and data protection management.

The study population comprised randomised plasma-EDTA and serum frozen samples from blood, plasma (excluding convalescent) and platelet donations from July 2019 to October 2020. Donations collected since 19/07/2019 (week -24) to 19/10/2020 (week 43) were randomized to select a minimum of 150

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

donations per week. A total of 12,718 samples of 11,444 donors over 18 years old were included.

Laboratory data and analyses

All haematological and demographic data were extracted from electronic database eDelphyn (Hemasoft). Variables analyzed included age, sex, blood group, and laboratory data.

Major laboratory markers were extracted from our donation database. Routine blood examinations included leukocyte (WBC), neutrophil, lymphocyte, platelet, monocyte, eosinophil and basophil counts (cells*10^3/µL) and their percentages. Serum immunoglobulins IgG, IgA and IgM (mg/dL), haemoglobin (Hb), haematocrit (HCT) and corpuscular mean volume were analysed as well.

An automated chemiluminiscence double-antigen sandwich immunoassay for the in vitro semi quantitative detection of total antibodies to SARS-CoV-2 in human serum and plasma was performed. The target antigen of this immunoassay is a recombinant nucleocapsid (N) protein. Elecsys® Anti-SARS-CoV-2 (Roche, Basel, Switzerland) detects antibodies correlating with virus-neutralizing ones and is therefore useful to help characterize the immune reaction to SARS-CoV-2 [9, 10]. Immunoassay was validated by our serology lab by testing of 6 pairs of samples (plasma EDTA and serum) from diagnosed PCR-positive, symptomatic cases infected by mid-April, that were previously reported positive by the Spanish National Microbiology Centre, and checked to be as well positive for IgG (Chemiluminiscence, N protein, Abbott Alinity S, Chicago USA) and IgA (ELISA, S protein, Euroimmunn, Lübeck, Germany) antiSARS-CoV-2. Another set of ten prepandemic samples, therefore supposed to be negative, were equally analyzed. A 100% concordance was yielded by these validation assays. The cut-off was that recommended by manufacturer (OD>1 to report reactivity). Researchers performing anti SARS-CoV-2 analyses were blind to the condition of

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

COVID-19 convalescence and to any other characteristic of the donors or to the donation dates.

Statistical analysis

Demographic and clinical characteristics of patients are expressed as their mean and standard deviation (SD) for continuous variables and frequency distributions are reported for categorical variables. Age was analysed both as continuous and categorical variable; in the latter case was recoded into 4 groups: <30, 30-45, 45-60, 60-75 years old.

Kolmogorov-Smirnov test was performed on each continuous variable to contrast normality. Only IgG and IgM serum levels followed normal distributions, therefore non-parametric Mann-Whitney U test was performed to compare laboratory values. To contrast the hypothesis of independence within categorical variables, Pearson's Chi-square and Fisher's exact test were carried out. All tests were calculated with a confidence level of 0.05.

Results

A total of 12,718 randomized donations (either whole blood, plasmapheresis or platelet apheresis) were tested for total anti SARS-CoV2 antibodies. Donors made up 11,444, 60.91% males, aged 18-75, average 46+/-13, 45.8% A, 40.3% O, 10.56% B, 3.31% AB.

Seropositivity rate grew up from week 11 to week 25, reaching a 11.1% peak, with just subtle descents until week 43 when 2nd wave arose in our country. Plateau was reached by the last week of May 2020, 11 weeks after close lockdown in Spain (that begun in March, 15th) and 17 weeks after 31/01, the date of the first declared case in or country. 660 out of 9,886 single donors were positive within weeks 11 to 43, that makes a seroprevalence of 6.73% at the end of the first wave.

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Three 2019 donations were reactive (from July, September and October) but none of them were positive when testing separately IgG, IgA or IgM. Their ODs were 1.05, 1.08 and 5.46 respectively. 1,142 donations from year 2019 were analyzed.



Figure 1. COVID-19 seropositive donation rate 2020 evolution by weeks. Temporal series' model (mobile median t=6; exponential smoothing model R[2]=0.991;p<0.001)

No differences in anti SARS-CoV2 reactivity due to sex, age or blood group of donors were found (Table 1).

	Negative		Positive	
	n	%	n	%
Female	4531	38.1%	164	40.3%
Male	7375	61.9%	243	59.7%
<30	3551	29.8%	104	25.6%
30 to 45	5036	42.3%	180	44.2%
45 to 60	1151	9.7%	42	10.3%
60 to 75	2168	18.2%	81	19.9%
A	5411	45.5%	198	48.6%
AB	423	3.6%	16	3.9%
B	919	7.7%	22	5.4%
O	5151	43.3%	171	42.0%

Table 1. Sex. age range and blood group of positive/negative anti SARS-COV2 donations analysed

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Immunoglobulin levels didn't show any differences as comparing positive and negative donations. Haemoglobin (14.9 vs 14.7 g/dL; p<0.001) and haematocrit (45.2% vs 44.4%;p<0.001) were both significantly lower in positive donations . Leukocyte count (WBC) was as well slightly lower (7.23 vs 7.06 cells*10^3/µL; p=0.026) (Table 2). A trend was found of lower number of neutrophils (4.3 vs. 4.2 cells*10^3/µL; p=0.117), lower count of monocytes (0.46 vs. 0.45 cells*10^3/µL; p=0.117) and higher percent of basophils (0.49% vs 0.51%; p=0.131).

As layering data by sex (Table 3), the fact arose that haematocrit (46.8% vs 45.9%; p<0.001) and haemoglobin (15.5 vs 15.3 g/dL; p<0.001) were significantly lower just in males and that positive females had significantly less WBC (7.67 vs 7.25 cells*10^3/µL;p=0.027) and neutrophil numbers (4.53 vs 4.27 cells*10^3/µL;p=0.014).

Some trends were found as well related to sex. Regarding positive women neutrophil percent would be lower (59.4% vs 58.10% p=0.065), with a higher lymphocyte percent (31.7% vs 33.10%; p=0.074) a lower platelet count (261 vs 255 cells*10^3/µL; p=0.152), monocyte count (0.46 vs 0.44 cells*10^3/µL; p=0.132) and basophil percent (0.5% vs 0.4%; p=0.060). Anaemia was more frequent in positive male donors as (6.1% vs 9.6%; p=0.031), A trend of. No other significant differences were found either in males, females or overall. Figure 2 summarize these findings.

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

	Overall	Male	Female
Hb	↓	↓	-
Hematocrite	↓	↓	-
Leukocyte count	↓	-	↓
Platelet count	-	-	↓
Neutrophil count	↓	-	↓
Neutrophil %	-	-	↑
Lymphocyte count	-	-	↓
Lymphocyte %	-	-	↓
Monocyte count	↓	-	↓
Basophil %	↑	-	↓

Figure 2. Haematological features in SARS-CoV-2 positive donations. Intense-coloured arrows represent significant differences. Light-coloured arrows represent statistical trends.

Discussion

A slightly lower seroprevalence than that found in general population was found among blood donors without COVID-19 antecedents. The 6.73% seroprevalence we found is a little lower than that reported in the seroprevalence study ENE-COVID-19 promoted by the *Instituto Nacional the Epidemiología* [11], where it is reported that a 7.2% of the participants in our region would have anti SARS-CoV2 IgG antibodies by the end of June 2020. Almost one quarter people in our region (25.51% according to National Institute of Statistics, INE 2020 data) is older than 65 and elderly are necessarily underrepresented in this study as it comprises blood donors. That happens as well with population aged less than 18 (under 4.5% in our region). One limitation of this study is that of age, restricted to 18-75 years old, but it would make just a little difference of 0.5% in seroprevalence estimation. Immunization rate would be a bit higher regarding the fact that some individuals do not exhibit antibodies but still mount an efficient specific T-cell response [2]

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Perhaps the main strength of our study is the large number of samples we randomized and tested along almost one year. The first recorded COVID-19 case in Spain was reported on 31/01/2020, but 3 positive donations were found as testing samples collected along 2019. That could be meaningful in two opposite ways: one possible explanation would be cross reactivity to seasonal cold coronaviruses and the other would be that SARS-CoV-2 might have been circulating at least since 2019 summer.

It is now known that up to 28% people would have protection against SARS-CoV-2 due to cross reaction to other coronaviruses [2]. It has been checked that long-term cross-reactive both T-cell and antibodies can be a correlate of protections against COVID-19 [12].Asymptomatic or mild cases couldn't be diagnosed or reported until the first tests were developed in the first term of 2020. There are other reports about SARS-CoV-2 circulating in Europe along 2019. Italy's Ministry of Health reported high levels of unusual strains of flu and pneumonia concentrated in the area around Milan and appearing in 17 of Italy's 20 regions [13]. Our three 2019 positive donors would be even earlier cases, but the simplest explanation would be that of cross reaction. In fact, we cannot 100% ascertain whether some of the positives along the period of study might be cross reactions as well or both reactive due to SARS-CoV-2 infection together with previous coronavirus immunity.

Conversely to clinical forms of COVID-19 [14,15] neither age nor sex have an influence on the probability to develop an asymptomatic COVID-19 infection in our cohort. Several smaller seroprevalence reports from European countries support this feature [16-20]. It may be therefore ascertained that age and sex do not have a role in SARSCoV-2 infection susceptibility, but only in their progression to severe forms.

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Blood group has been reported elsewhere [7,21-23] to confere susceptibility or determine severity of SARS-CoV2 infection. Most studies do not separate susceptibility and severity. It should be noticed that there are no large studies characterizing asymptomatic cases in literature, perhaps this is one of the reports comprising more asymptomatic individuals. Relationship of ABO system with susceptibility is not supported by our data. We excluded convalescent plasma donors, opposite to other studies, that focused into these asymptomatic positive donors [22]. Perhaps blood group might be related only to symptomatic cases and would be therefore related to severity but not related to asymptomatic SARS-CoV-2 infection. Another surface antigens such as HLA or KIR might be as well involved and should be studied.

Several blood count anomalies have been reported to be associated to SARS-CoV2 infection, notably lymphopenia and neutrophilia are related to severest forms [24]. Our data conversely reveal that asymptomatic positive women had a significant lower count of WBC and neutrophils as compared to negative ones. Similar low counts of WBC and neutrophils have been reported in young (<19) cohorts, comprising mainly mild and asymptomatic cases [25]. Perhaps this feature might be therefore a correlate of mildness. Elevation of monocytes have been elsewhere reported in short series of mild cases [26]. Our observation in will be in the same line of those findings but a gender bias cannot be discarded so far seropositive women would go in the opposite direction.

Several reports about haemolytic anaemia secondary to SARSCoV-2 have been published [27-30]. We cannot discard the possibility of a mild silent haemolytic anaemia in asymptomatic cases. Again, little analysis of asymptomatic cases is available by the moment.

We can conclude that seroprevalence estimations through blood donation analysis resemble data obtained from population-based surveys. Sex and age

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

would not affect COVID-19 susceptibility but its severity. Gender differences are present even in asymptomatic individuals: females are known to develop milder COVID-19, this fact might be related to a lower WBC count whereas positive males although asymptomatic, present anaemia more frequently than negative ones. Further studies in large cohorts are needed to confirm these gender differences and to characterize asymptomatic COVID-19 cases as they can help better understand immune response to COVID-19, its pathogenesis and prognosis.

Availability of data and materials

The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request and after mandatory approval of proposals by the Valladolid Este Ethical Committee

References

1. Busch MP, Stone M. Serosurveillance for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Incidence Using Global Blood Donor Populations. Clin Infect Dis. 2020;72(2):254-256
2. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020 Oct 1;183(1):158-168.e14. doi: 10.1016/j.cell.2020.08.017. Epub 2020 Aug 14. PMID: 32979941; PMCID: PMC7427556.
3. Wouters E, Steenhuis M, Schrezenmeier H, Tiberghien P, Harvala H, Feys HB, van der Schoot E. Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary. Vox Sang. 2021 May;116(5):493-496. doi: 10.1111/vox.13060. Epub 2020 Dec 23. PMID: 33368373.
4. Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. *JAMA Netw Open*. 2021;4(1):e2033706

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

5. Friston K, Costello A, Pillay D. 'Dark matter', second waves and epidemiological modelling. *BMJ Glob Health*. 2020;5(12):e003978

6. Netea MG, van der Meer JW, van Crevel R. BCG vaccination in health care providers and the protection against COVID-19. *J Clin Invest*. 2021;131(2):e145545

7. Gallais F, Velay A, Nazon C, Wendling MJ, Partisani M, Sibilia J, Candon S, Fafi-Kremer S. Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France. Emerg Infect Dis. 2021;27(1):113–21

8. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. *Antiviral Res*. 2020;181:104880

9. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. *J Clin Virol*. 2020;129:104480

10. Müller L, Ostermann PN, Walker A, et al. Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting [published online ahead of print, 2021 Feb 3]. *Eur J Clin Microbiol Infect Dis*. 2021;1-9

11. Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, et al. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. *BMJ*. 2020;371:m4509

12. Poonia B, Kottilil S. Immune Correlates of COVID-19 Control. *Front Immunol*. 2020;11:569611

13. Murtas R, Decarli A, Russo AG. Trend of pneumonia diagnosis in emergency departments as a COVID-19 surveillance system: a time series study. BMJ Open. 2021;11(2):e044388.

14. Jurado A, Martín MC, Abad-Molina C, et al. COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study. Immun Ageing. 2020;17:22

15. Martín MC, Jurado A, Abad-Molina C, Orduña A, Yarce O, Navas AM, et al. The age again in the eye of the COVID-19 storm: evidence-based decision making. Immun Ageing. 2021 May 20;18(1):24. doi: 10.1186/s12979-021-00237-w. PMID: 34016150; PMCID: PMC8134808.

16. Dickson E, Palmateer NE, Murray J, et al. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic. *Public Health*. 2021;190:132-134

17. Hallal PC, Hartwig FP, Horta BL, et al. SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. *Lancet Glob Health*. 2020;8(11):e1390-e1398.

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

18. Bogogiannidou Z, Vontas A, Dadouli K, et al. Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. *Euro Surveill*. 2020;25(31):2001369

19. Biggs HM, Harris JB, Breakwell L, et al. Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(29):965-970

20. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet*. 2020;396(10247):313-319

21. Pendu JL, Breiman A, Rocher J, Dion M, Ruvoën-Clouet N. ABO Blood Types and COVID-19: Spurious, Anecdotal, or Truly Important Relationships? A Reasoned Review of Available Data. *Viruses*. 2021;13(2):160

22. Muñiz-Diaz E, Llopis J, Parra R, et al. Relationship between the ABO blood group and COVID-19 susceptibility, severity and mortality in two cohorts of patients. *Blood Transfus*. 2021;19(1):54-63

23. Zalba Marcos S, Antelo ML, Galbete A, Etayo M, Ongay E, García-Erce JA. Infection and thrombosis associated with COVID-19: Possible role of the ABO blood group. Infección y trombosis asociada a la COVID-19: posible papel del grupo sanguíneo ABO. Med Clin (Barc). 2020;155(8):340-343. doi:10.1016/j.medcli.2020.06.020

24. Agbuduwe C, Basu S. Haematological manifestations of COVID-19: From cytopenia to coagulopathy. *Eur J Haematol*. 2020;105(5):540-546

25. Toba N, Gupta S, Ali AY, ElSaban M, Khamis AH, Ho SB, Popatia R. COVID-19 under 19: A meta-analysis. Pediatr Pulmonol. 2021 Jun;56(6):1332-1341. doi: 10.1002/ppul.25312. Epub 2021 Feb 25. PMID: 33631060; PMCID: PMC8013606

26. Gatti A, Radrizzani D, Viganò P, Mazzone A, Brando B. Decrease of Non-Classical and Intermediate Monocyte Subsets in Severe Acute SARS-CoV-2 Infection. Cytometry A. 2020 Sep;97(9):887-890. doi: 10.1002/cyto.a.24188. Epub 2020 Aug 14. PMID: 32654350; PMCID: PMC7404377

27. Gruden G, Beggiato E, Camerino E, Capriotti S, Canepa S, Scandella M, Avolio M, Pittalunga F, Barutta F, Durazzo M. Treatment with eltrombopag of severe immune thrombocytopenia and hemolytic anemia associated with COVID-19 pneumonia: a case report. Ther Adv Hematol. 2021 Apr 27;12:20406207211011353. doi: 10.1177/20406207211011353. PMID: 33995989; PMCID: PMC8082984.

28. Liput JR, Jordan K, Patadia R, Kander E. Warm Autoimmune Hemolytic Anemia Associated With Asymptomatic SARS-CoV-2 Infection. Cureus. 2021 Mar 25;13(3):e14101. doi: 10.7759/cureus.14101. PMID: 33927918; PMCID: PMC8075761.

29. Georgy JT, Jayakaran JAJ, Jacob AS, Gunasekaran K, Korula PJ, Devasia AJ, Iyadurai R. Evans syndrome and immune thrombocytopenia in two patients with COVID-19. J Med Virol. 2021 May;93(5):2642-2644. doi:

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

10.1002/jmv.26906. Epub 2021 Mar 9. PMID: 33634495; PMCID: PMC8013600.

30. Mausoleo A, Henriquez S, Goujard C, Roque-Afonso AM, Noel N, Lambotte O. Severe IgA-mediated autoimmune hemolytic anemia triggered by SARS-CoV-2 infection. Leuk Lymphoma. 2021 Feb 22:1-5. doi: 10.1080/10428194.2021.1888378. Epub ahead of print. PMID: 33618609.

31. Goud PT, Bai D, Abu-Soud HM. A Multiple-Hit Hypothesis Involving Reactive Oxygen Species and Myeloperoxidase Explains Clinical Deterioration and Fatality in COVID-19. Int J Biol Sci. 2021 Jan 1;17(1):62-72

32. Dattilo M. The role of host defences in Covid 19 and treatments thereof. *Mol Med*. 2020;26(1):90

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Tables

		n	mean	median	SD	IQR
Age	Negative	11906	44.0	**45.8**	12.8	34.2-54.2
	Positive	407	44.2	**46.5**	13.0	32.8-54.8
IgA	Negative	194	236.9	**223.5**	101.3	163-292
	Positive	5	224.4	**274.0**	92.3	134-282
IgG	Negative	194	1065.4	**1037.5**	217.4	910-1185
	Positive	5	1123.8	**1095.0**	249.9	924-1229
IgM	Negative	194	113.3	**100.5**	64.8	69-138
	Positive	5	103.0	**89.0**	41.7	78-97
WBC (p=0.026)	Negative	9759	7.4	**7.2**	1.8	6.13-8.49
	Positive	346	7.2	**7.1**	1.6	6.11-8.12
Hb (p<0.001)	Negative	11218	14.9	**14.9**	1.3	14-15.8
	Positive	386	14.7	**14.7**	1.2	13.8-15.4
Hematocrite (p<0.001)	Negative	11218	45.1	**45.2**	3.5	42.7-47.6
	Positive	386	44.5	**44.4**	3.5	42.3-46.6
Platelets	Negative	11217	247.9	**243.0**	54.3	211-280
	Positive	386	247.3	**242.5**	55.7	206-276
Neutrophil count	Negative	11217	4.4	**4.3**	1.4	3.44-5.19
(p=0.117)	Positive	386	4.3	**4.2**	1.2	3.34-5.03
Neutrophil %	Negative	11217	58.8	**58.9**	7.5	53.8-63.9
	Positive	386	58.5	**58.7**	7.1	54.3-63.4
Lymphocyte count	Negative	11216	2.3	**2.3**	0.7	1.86-2.72
	Positive	386	2.3	**2.2**	0.6	1.89-2.64
Lymphocyte %	Negative	11216	31.7	**31.5**	6.9	27-36.2
	Positive	386	32.1	**32.4**	6.6	27.3-36.1
Monocyte count (p=0.131)	Negative	11216	0.5	**0.46**	0.1	0.38-0.56
	Positive	386	0.5	**0.46**	0.1	0.37-0.54
Monocyte %	Negative	11216	6.5	**6.4**	1.5	5.5-7.4
	Positive	386	6.5	**6.4**	1.4	5.5-7.3
Eosinophil count	Negative	11217	0.2	**0.2**	0.1	0.09-0.23
	Positive	386	0.2	**0.1**	0.1	0.09-0.22
Eosinophil %	Negative	11217	2.5	**2.1**	1.8	1.3-3.2
	Positive	386	2.4	**2.0**	1.7	1.3-3.1
Basophil count	Negative	11217	0.0	**0.0**	0.0	0.02-0.04
	Positive	386	0.0	**0.0**	0.0	0.02-0.04
Basophil %	Negative	11217	0.5	**0.5**	0.2	0.3-0.6
	Positive	386	0.5	**0.5**	0.3	0.4-0.6

Table 2. Descriptive analysis of age. immunoglobulins (mg/dL). Hb(g/dL), hemogram counts (cells*10[3]/µL) and percentages of reactive and non-reactive donations

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

			n	mean	median	SD	IQR
Age	Female	Negative	4531	42.0	**43.50**	13.3	30.3-53.3
		Positive	164	42.1	**45.39**	13.6	28.6-53.1
	Male	Negative	7375	45.2	**46.81**	12.2	36.7-54.8
		Positive	243	45.7	**46.98**	12.5	35.5-55.9
IgA	Female	Negative	54	214.3	**200.00**	97.0	157-250
		Positive	3	235.3	**274.00**	105.5	116-316
	Male	Negative	140	245.6	**233.50**	101.9	176.5-302.5
		Positive	2	208.0	**208.00**	104.7	134-282
IgG	Female	Negative	54	1076.4	**1062.50**	191.3	964-1186
		Positive	3	1082.7	**1095.00**	152.9	924-1229
	Male	Negative	140	1061.2	**1029.00**	227.2	903-1181.5
		Positive	2	1185.5	**1185.50**	436.3	877-1494
IgM	Female	Negative	54	143.1	**129.50**	64.6	94-169
		Positive	3	114.3	**89.00**	53.7	78-176
	Male	Negative	140	101.8	**90.00**	61.3	64.5-121
		Positive	2	86.0	**86.00**	15.6	75-97
MCV	Female	Negative	3618	91.2	**91.50**	4.8	88.4-94.4
		Positive	142	91.2	**91.40**	4.1	88.9-93.5
	Male	Negative	6141	90.9	**91.00**	4.6	88.1-93.8
		Positive	204	90.6	**91.00**	4.8	88-94.1
WBC	Female*	Negative	3618	7.8	**7.69**	1.9	6.49-9
		Positive	142	7.4	**7.21**	1.5	6.27-8.26
	Male	Negative	6949	7.2	**7.02**	1.8	5.99-8.2
		Positive	229	7.1	**6.98**	1.6	6.01-8.03
Hb	Female	Negative	4269	13.8	**13.80**	0.9	13.2-14.4
		Positive	157	13.7	**13.80**	0.9	13.2-14.3
	Male*	Negative	6949	15.5	**15.50**	1.0	14.9-16.2
		Positive	229	15.3	**15.30**	1.0	14.7-15.8
HCT	Female	Negative	4269	42.4	**42.30**	2.7	40.6-44
		Positive	157	42.1	**42.00**	2.5	40.5-43.6
	Male*	Negative	6949	46.8	**46.80**	2.8	45-48.6
		Positive	229	46.2	**45.90**	3.0	44.3-47.7
PLT	Female	Negative	4268	265.9	**261.00**	56.6	228-300
	(t)	Positive	157	261.0	**255.00**	60.5	219-296
	Male	Negative	6949	236.8	**233.00**	49.6	204-266
		Positive	229	237.9	**234.00**	50.2	203-266
Neutrophil count	Female*	Negative	4268	4.7	**4.53**	1.4	3.65-5.47
		Positive	157	4.4	**4.27**	1.2	3.56-5.08
	Male	Negative	6949	4.3	**4.10**	1.4	3.34-4.95
		Positive	229	4.2	**4.10**	1.2	3.24-4.97
Neutrophil %	Female	Negative	4268	59.2	**59.40**	7.4	54.2-64.3
		Positive	157	58.1	**58.10**	7.2	54-62.9
	Male	Negative	6949	58.6	**58.70**	7.5	53.6-63.6
		Positive	229	58.8	**58.70**	7.0	54.6-63.5

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Lymphocyte count	Female*	Negative	4267	2.5	**2.39**	0.7	1.97-2.88
		Positive	157	2.4	**2.35**	0.6	2.02-2.81
	Male	Negative	6949	2.2	**2.18**	0.6	1.8-2.62
		Positive	229	2.2	**2.17**	0.6	1.8-2.51
Lymphocyte %	Female	Negative	4267	32.0	**31.70**	6.9	27.4-36.5
	(t)	Positive	157	33.0	**33.10**	7.0	28.4-37
	Male	Negative	6949	31.5	**31.30**	6.9	26.8-36.1
		Positive	229	31.4	**31.70**	6.3	26.7-35.6
Monocyte count	Female	Negative	4267	0.5	**0.46**	0.1	0.37-0.55
	(t)	Positive	157	0.5	**0.44**	0.1	0.36-0.52
	Male	Negative	6949	0.5	**0.46**	0.1	0.38-0.56
		Positive	229	0.5	**0.47**	0.1	0.38-0.55
Monocyte %	Female	Negative	4267	6.1	**6.00**	1.4	5.1-6.9
		Positive	157	6.1	**6.00**	1.4	5.2-6.9
	Male	Negative	6949	6.7	**6.60**	1.5	5.7-7.6
		Positive	229	6.7	**6.70**	1.4	5.8-7.6
Eosinophil count	Female	Negative	4268	0.2	**0.14**	0.1	0.09-0.21
		Positive	157	0.2	**0.13**	0.1	0.09-0.19
	Male	Negative	6949	0.2	**0.16**	0.1	0.1-0.24
		Positive	229	0.2	**0.15**	0.1	0.09-0.23
Eosinophil %	Female	Negative	4268	2.2	**1.80**	1.6	1.2-2.8
		Positive	157	2.3	**1.80**	1.7	1.1-2.8
	Male	Negative	6949	2.7	**2.20**	1.8	1.4-3.4
		Positive	229	2.5	**2.10**	1.7	1.4-3.2
Basophil count	Female	Negative	4268	0.0	**0.03**	0.0	0.02-0.05
		Positive	157	0.0	**0.04**	0.0	0.02-0.05
	Male	Negative	6949	0.0	**0.03**	0.0	0.02-0.04
		Positive	229	0.0	**0.03**	0.0	0.02-0.04
Basophil %	Female	Negative	4268	0.5	**0.40**	0.2	0.3-0.6
	(t)	Positive	157	0.5	**0.50**	0.3	0.3-0.6
	Male	Negative	6949	0.5	**0.50**	0.2	0.3-0.6
		Positive	229	0.5	**0.50**	0.2	0.4-0.6

*p<0.01

(t) p<0.2

Table 3. Descriptive analysis of age, immunoglobulins (mg/dL), Hb(g/dL), MCV, hemogram counts (cells*10[3]/µL) and percents, of reactive and non-reactive donations by sex.